ArticleAsian biomedicine : research, reviews and news2026
Clinical efficacy and pharmacokinetic study of antituberculosis treatment in patients with end-stage renal disease undergoing hemodialysis.
Article in Asian biomedicine : research, reviews and news, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with end-stage renal disease (ESRD) undergoing hemodialysis exhibit a 10-25 times greater risk of tuberculosis (TB), underscoring the urgent need for optimized treatment strategies to improve prognosis. Objective: The present study evaluates the efficacy and pharmacokinetics of personalized anti-TB dosing in hemodialysis patients with ESRD and TB, to guide treatment optimization. Methods: This retrospective study included 90 hemodialysis patients with ESRD and TB (2020 - 2024). The control group (n = 45) received conventional anti-TB dosing; the study group (n = 45) received individualized dosing/timing. All received HRZE (isoniazid, rifampicin, pyrazinamide, ethambutol) and high-flux hemodialysis or hemodiafiltration. Efficacy endpoints included sputum conversion (4, 8, and 12 weeks), imaging at 12 weeks, and clinical effectiveness. Blood samples were collected before/during/after/dialysis intervals to calculate C Result: No significant baseline differences existed between groups ( Conclusions: For hemodialysis patients with ESRD and TB, tailoring anti-TB drug regimens based on PK profiles can enhance efficacy and minimize adverse effects, offering a safe and personalized treatment pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.